Balyasny Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Balyasny Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-8,251	Closed	-$647K	–	1620
2019 Q1	$647K	Buy	+8,251	New	+$625K	﹤0.01%	1131
2018 Q4	–	Sell	-8,913	Closed	-$1.53M	–	1580
2018 Q3	$1.53M	Buy	8,913 +3,051	+52%	+$460K	0.01%	1070
2018 Q2	$758K	Buy	+5,862	New	+$654K	﹤0.01%	1209
2017 Q4	–	Sell	-6,917	Closed	-$587K	–	2196
2017 Q3	$587K	Buy	+6,917	New	+$548K	﹤0.01%	1308
2015 Q2	–	Sell	-77,863	Closed	-$3.75M	–	1243
2015 Q1	$3.75M	Buy	+77,863	New	+$2.98M	0.03%	524

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Balyasny Asset Management's LGND Position: Q2 2019 in Review

Balyasny Asset Management sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 8,251 shares — an estimated $647K sold.

Balyasny Asset Management first reported a position in LGND in Q1 2015 and held it in 5 quarters. The position peaked at $3.75M in Q1 2015. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Balyasny Asset Management reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Balyasny Asset Management sold 8,251 Ligand Pharmaceuticals shares in Q2 2019, an estimated $647K.
Balyasny Asset Management first reported a position in Ligand Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Balyasny Asset Management's Ligand Pharmaceuticals position peaked at $3.75M in Q1 2015.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Balyasny Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.